

# NCI CDISC Implementation Committee

*Neesha Desai*

# Agenda

- **CTEP CDISC Project Updates**

# CTEP CDISC Harmonized Standard Forms Roadmap

v03/23/2022

R1 Oct 20, 2020	R3 Oct 30, 2020	R4 Jan 27, 2021	R5 March 29, 2021	R6 May 2, 2022	R7 Pending on CDISC	R8 June 7, 2021	R9 TBD, 2022*		
RECISTv1.1	Physical Examination	Adverse Event/ Serious Adverse Event CTCAE v4.0	Diagnosis Administrative	Diagnosis Intervention	Diagnosis	Radiation Therapy	Staging AJCC Edition 8, Breast	Brief Pain Inventory-BPI	CTEP CDISC FACT-P (Version 4)
Screening	Follow-Up/ Survival	Adverse Event/ Serious Adverse Event CTCAE v5.0	Diagnosis Gross Pathology	Equipment	iRECIST	Response	Staging AJCC Edition 8, Prostate	EPIC-26 Short Form	CTEP CDISC EORTC QLQ- C30 (ver. 3)
Off Treatment	Lost to Follow- Up	Adverse Event/ Serious Adverse Event CTCAE v5.0	Enrollment	Image Administration	irRC	Study Agent Administration	Staging AJCC Edition 8, Colorectal	EQ-5D-3L (Version 1)	CTEP CDISC PROMIS Item Bank v1.0 - Fatigue - Short Form 7a
Off Study	Eligibility	Consent	Laboratory Test/Results	Metastasis	irRECIST	CT Image Acquisition	EQ-5D-5L (Version 1)	CTEP CDISC XML Download (MDADI) (Version 1.0)	CTEP CDISC LASA-6
R2 No Active Use Case	Demography	Consent Withdrawal	Prior Therapies	PET Imaging Agent	PET Emissions Scan	CT Imaging Agent		CTEP CDISC EORTC QLQ- H&N35	
	Medical History	Consent Withdrawal Specimen	Registration	PET Patient Prep	Diagnosis Microscopic Pathology	Image Quality			
TRIAD	Surgery	Consent Withdrawal Quality of Life Study	Staging AJCC Edition 8 Lung	Progression					
	Vital Signs			Protocol Deviations					
	Concomitant Medication			PET Equipment QC Assessment					
	Diagnosis Intervention			Participant Identification					

Pending	
Not Started	
In Progress	
Completed	

# CTEP CDISC Project Update

## ■ R6

- Project team is continuing to review content
- Estimated release date: May 2<sup>nd</sup>, 2022

Total Items For Review: 300  
Completed: 238  
Pending: 62

## ■ R7

- CDISC must go through the process of getting permissions from copyright holders for every copyrighted instrument that they are requested to make standards for. The QRS team communicated AJCC v8 copyright permission was actually sought over a year ago. CDISC is awaiting AJCC copyright permission to be granted before they can begin standards development to fulfill your request.

# CTEP CDISC Project Update

Total Items For Review: 177  
Completed: 0

## ■ R9

- CDISC SME will touch base with CDISC on their plans for the following instruments as there are no existing CDISC testcodes/CT.
  - CTEP CDISC PROMIS Item Bank v1.0 - Fatigue - Short Form 7a
  - CTEP CDISC XML Download  
M.D. Anderson Dysphagia Inventory (MDADI) (Version 1.0)
  - CTEP CDISC LASA-6
  - CTEP CDISC EORTC QLQ-H&N35
- There are existing testcodes/CT for the following instruments
  - CTEP CDISC FACT-P (Version 4)
  - CTEP CDISC EORTC QLQ-C30 (version 3)
- Per CDISC SME recommendation, we should move forward to harmonize this content using the CTEP CDISC naming conventions.
- Total of 6: 2 are part of focus for pending follow up with CDSIC
- Estimated release date: TBD based on CDISC feedback

# CTEP CDISC Project Update

- **NCI CTEP CDISC Policy and Governance Document**
  - Updated language to include management of new study builds
  - Releasing updated document on March 28, 2022
  
- **ALS v7.1 Beta released for LPO UAT on March 10, 2022**
  - LPO testing activities have started
  - Questions should be sent to the NCI CDISC mailbox and will be triaged to the CTSU/Westat team

# Phase 3 CTEP CDISC Standards

**NSVs/Supplemental  
Content**

Fragments

Biomarkers

Disease Specific  
Content

PROs

PRO-CTCAE

# Phase 3 Status Update

## ■ NSVs/Supplemental Content

- Presented review process for NSVs
- Provided Catalog/inventory listing of all received NSVs to LPOs
- Continuing with Theradex content
- Will continue content/comment review in the CDISC Harmonization WG Meeting

## ■ Fragments

- Catalog/inventory listing has been created, pending review to be initiated after NSVs activities

## ■ Biomarkers

- CDISC Project Team reviewing Theradex forms to understand how biomarkers are being used.
- CDISC SME reviewing the catalog/inventory listing **\*6,108 values for 1 CDE**
- Next steps: Identify a process to handle biomarkers with CDISC Harmonization.



## Phase 3 Status Update

### ■ Disease Specific Content

- Catalog/inventory listing of all disease specific content from caDSR has been created, review to be initiated after NSVs activities

### ■ PROs

- Catalog/inventory listing has been created, pending review to be initiated after NSVs activities
- CDISC harmonization with CTEP CDISC SME and identification of timeline is pending

# Phase 3 Status Update

## ■ CDISC PRO-CTCAE V1.0 supplement

- CDISC is in the process of updating and sending the CDISC copyright letter for NCI's approval to allow CDISC to implement the CDISC PRO-CTCAE supplement
- Next review steps:
  - Draft supplement review by NIH/NCI staff
  - CDISC internal review
  - FDA priority QRS instrument review by the FDA QSuRT staff
  - CDISC public review for 30 days; all comments resolved
  - Finalized and posted on the CDISC QRS webpage for user access
- NCI CTEP CDISC project team will begin harmonization activities

# Next Steps

- Next Meeting
  - May 25<sup>th</sup>, 2022
  - \*\*if there are any urgent updates that need to be shared, we will schedule an impromptu meeting

# Appendix

*CTSU Standard Forms ALS Reminders*  
*NCI CDISC Waiver Request Process & Examples*  
*CDISC Harmonization Workflow*  
*NCI CBIIT: CDEs for EC Forms Overview*  
*CDISC Implementation Workflow*  
*CTSU Change Matrix*  
*eCRF Build Scenarios*  
*LPO I.A.: Beta Release GLIB*

# CTSU Standard Forms ALS- v7.1 Planning


- Projected Next Steps – *Timeline TBD, late 2020*
  - NCI PM receives & incorporates CTIS feedback
  - Focus Group finalizes review & decisions
  - NCI PM summarizes & prepares documentation for LPO-requested changes
  - LPOs review & achieve consensus for LPO-requested changes
  - CTSU manages technical updates development & testing
  - NCI PM verifies implementation plan details & release dates
    - CDISC CTSU Standard Forms ALS v7.1
      - Includes CDISC SME & NRDS compliance reviews
    - CTSU Central Study ALS v7.1
      - Includes upload to LPO Rave URLs

# CTSU Standard Forms ALS- *Reminders*

- CTSU Central Study ALS details
  - Houses custom functions (CFs) needed for CTSU integrations
  - Allows for updates to be made without requiring LPO migration activities
  - Maintained by CTSU for all LPO urls except for the Alliance Rave url
    - CTSU does not have access to the Alliance Rave url
    - Alliance manages/ maintains Central Study updates for their url
- CDISC CTSU Standard Forms must be used as-is
  - Questions should not be removed
  - Questions can be added as needed by LPOs
- CTSU is working with multiple LPOs individually on integration issues
  - Patches are applied as needed across LPOs for common issues
  - Patches are applied as needed per issues identified by an LPO
    - as per LPO-specific Rave study build
  - CTSU will post challenges/issues/resolutions details to the Collaboration Portal

# NCI Requirement- *Waiver Request Process*

- Send email to [ncicdiscsupport@nih.gov](mailto:ncicdiscsupport@nih.gov)
- Specify the following information in the email:
  - Protocol #
  - OEWG Date
  - Initial Production Date
  - New Production Date (if known)
  - Waiver Request Details

 To...   
Cc...   
Subject

*{insert LPO}* is requesting a waiver for the study specified below:

Protocol #	OEWG Date	Initial Production Date	New Production Date	NCI CDISC Waiver Request Details
<i>{insert protocol}</i>	<i>{insert date, mm/dd/yyyy}</i>	<i>{insert date, mm/dd/yyyy}</i>	<i>{insert date, mm/dd/yyyy}</i>	<i>{specify details regarding why the waiver is being requested, including cause of delay, considerations, etc.}</i>

## NCI Requirement- *Waiver Request Examples*

- Examples:
  - Acceptable waiver request: Study with an OEWG date of 12/1/19 whose activation is delayed due to drug supply until 3/15/20.
  - Unacceptable waiver request: Study with an OEWG date of 2/1/20 whose activation is delayed due to drug supply until 3/15/20. This study should have been built with the intention of meeting the original CDISC implementation date.



# CDISC Harmonization Workflow v06/25/2019

- 1) LPO submits new supplemental question details to CDISC Project team via ALS file within 15 business days of question implementation.
- 2) CDISC Project team adds the new supplemental question to the **CDISC LPO Supplemental Question Listing**<sup>1</sup>.
- 3) CDISC Project team prepares and submits the supplemental questions (partial or no match) to the CDISC Harmonization Working Group (WG).
- 4) CDISC Harmonization WG reviews, standardizes and harmonizes the supplemental question/s.
- 5) CDISC Project team prepares a supplemental questions review request for submission to CDSIC.
- 6) CDISC Project team submits and tracks review requests to CDISC.

## **Footnotes**

1. The **CDISC LPO Supplemental Question Listing** is a document created and maintained by the NCI CDISC Project team. This document will specify:
  - a. Supplemental questions that have been recently created and implemented by an LPO for a specific protocol;
  - b. Supplemental questions that have been harmonized/standardized by the **CDISC Harmonization WG** and submitted by the CDISC Project team to CDISC for review.

# Project Updates (1)

- **CDISC Mailbox**

- [ncicdiscsupport@nih.gov](mailto:ncicdiscsupport@nih.gov)

- **CDISC Wiki**

- CDISC Webinars, Recording and Slides Posted
  - LPO FAQs
  - CDISC LPO Impact Analysis Feedback Posted
  - CDISC Harmonization WG Meeting Materials

# NCI CBIIT: CDEs for EC Forms Overview

## 1. EC CDEs – *Inclusion/Exclusion Criteria*

- CDASH does not provide a variable for individual inclusion/exclusion questions
- Continue to curate these CDEs using your current process

### TI – Examples for Trial Inclusion/Exclusion Criteria Dataset

This example shows records for a trial that had two versions of inclusion/exclusion criteria.

Rows 1-3 show the two inclusion criteria and one exclusion criterion for version 1 of the protocol.


Rows 4-6 show the inclusion/exclusion criteria for version 2.2 of the protocol, which changed the minimum age entry from 21 to 18.

Row	STUDYID	DOMAIN	IETESTCD	IETEST	IECAT	TIVERS
1	XYZ	TI	INCL01	Has disease under study	INCLUSION	1
2	XYZ	TI	INCL02	Age 21 or greater	INCLUSION	1
3	XYZ	TI	EXCL01	Pregnant or lactating	EXCLUSION	1
4	XYZ	TI	INCL01	Has disease under study	INCLUSION	2.2
5	XYZ	TI	INCL02A	Age 18 or greater	INCLUSION	2.2
6	XYZ	TI	EXCL01	Pregnant or lactating	EXCLUSION	2.2

## 2. EC CDEs – Supplemental Qualifiers Domain Questions

- NCI CBIIT team will curate CDEs for the LPOs requesting assistance please submit request(s) to the NCI CDISC Mailbox
- Will curate only EC Forms where questions are not already curated CDASH or Inclusion/Exclusion
- For curation we will need CDISC details – LPOs provide map to SDTM:
  - Variable label
  - Variable name
  - Data format
  - List of values (if enumerated)

# CDISC Implementation Workflow



# CDISC Rave Global Library: CTSU Change Matrix

Rave Attribute	caDSR/ OCI Attribute	CTSU CDISC Global library	Change Management
Form Name	caDSR Form Long Name <i>(e.g., DEMOGRAPHICS)</i>	CDASH Domain Name <i>(e.g., DEMOGRAPHICS)</i>	<no change: same as caDSR>
Form OID	caDSR Form Long Name <i>(e.g., DEMOGRAPHICS)</i>	<b>2 letter CDASH Domain Name</b> <i>(e.g., DM)</i>	<b>Update by CTSU</b>
Variable OID	Short Name of the CDE <i>(e.g., RACE)</i>	CDASH/SDTM Variable Name <i>(e.g., RACE)</i>	<no change: same as caDSR>
Field Name	caDSR CDE Long Name + PID + MajorV + MinorV <i>(e.g., Race PID6343384_V1_0)</i>	Variable Label + PID + MajorV + MinorV <i>(e.g., Race PID6343384_V1_0)</i>	<no change: same as caDSR>
Field OID	2 letter domain prefix + CDASH/ SDTM variable <i>(e.g., RACE)</i>	2 letter domain prefix + CDASH/SDTM Variable Name <i>(e.g., RACE)</i>	<no change: same as caDSR>
Field Label	Question Text <i>(e.g., Which of the following five racial designations best describes you? (More than one choice is acceptable.))</i>	Question Text <b>or Variable label</b> <i>(e.g., Which of the following five racial designations best describes you? (More than one choice is acceptable.))</i>	<b>Update by CTSU</b> <b>**Specify the Variable label for Field Labels without question text **</b>
Data Dictionary Name	caDSR Value Domain Long Name + PID + MajorV <i>(e.g., CDISC_SDTM_RACE_PID6343345_V1_OF)</i>	caDSR Value Domain Long Name + PID + MajorV	<no change: same as caDSR>
Data Dictionary Values-User Data String	Permissible Value Meaning (PVM) <i>(e.g., Native Hawaiian or Other Pacific Islander)</i>	NCI preferred term <i>(e.g., Native Hawaiian or Other Pacific Islander)</i>	<no change: same as caDSR>
Data Dictionary Values-Coded Data String	Permissible Value (PV) <i>(e.g., NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)</i>	Submission Value <i>(e.g., NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)</i>	<no change: same as caDSR>
Format- Date	char - \$11	<b>dd MMM yyyy</b>	<b>Update by CTSU</b>
Format- Time	char - \$10	<b>24 hr HH:nn:ss</b>	<b>Update by CTSU</b>
Format- Char (W/ Dictionary)	char <i>(may be either the max length of dictionary value or extendable value;; e.g., \$100)</i>	char <i>(may be either the max length of dictionary value or extendable value; e.g., \$100)</i>	<no change: same as caDSR>
Format- Char (W/O Dictionary)	char -\$200	char -\$200	<no change: same as caDSR>
Format- Numeric	num	num	<no change: same as caDSR>
Control Type	<i>(e.g., DropDownList)</i>	<b>DATE/TIME update</b>	<b>Update by CTSU</b>
SAS Label	n/a	<b>Variable Label from SDTM; if no SDTM variable, use CDASH variable label</b>	<b>Update by CTSU</b>
Auto-Query for Required data entry	n/a	<b>SDTM -Required &amp; Expected Variables CDASH - HR and R/C</b>	<b>Update by CTSU</b>
Auto-Query for future Date	n/a	<b>Set flag in the CDISC Rave GLIB ALS</b>	<b>Update by CTSU</b> <b>**Applicable to all dates**</b>

# eCRFs Build Scenarios (1)

## Rave eCRFs may have different build scenarios:

- 1) Variables from a **single domain**
- 2) Variables from **multiple domains**
- 3) Custom variables that do not map to CDASH/SDTM

**1) Single Domain:** All variables in an eCRF are from a single domain.

*Example: Concomitant Medication (CM) domain*

- Set the CDISC Global library as the copy source for the study.
- Identify the Domain variables needed for the CRF.
- Use copy wizard to select and copy the variables from the domain identified for eCRF build.
- Multiple eCRFs can be built using the same domain by changing the FORM OID during the copy process.

## eCRFs Build Scenarios (2)

### 2) **Multiple Domains:** Variables in an eCRF are from more than one domain.

*Example: an Exposure form with variables from the EX and AE domains*

- Follow the steps specified in the “eCRFs Build Scenarios: Single Domain” slide to build an Exposure form with variables from the EX domain.
- Using the copy wizard, copy the required variables from the AE domain to the study draft.
- Add AE domain variables to an Exposure form:

#### **Option 1**

- Open the Exposure form; click add a new variable.
- Use the “**Find**” link on the variable definition screen to select the AE variable; click Apply to copy.

*Note: the “Find” link brings only the Variable OID, Format and Data/Unit dictionary, not the associated Field attributes.*

#### **Option 2**

- Download the ALS for the selected domains.
- Copy and paste the AE domain variables to the Exposure Form.
- Upload the ALS into Rave.

# eCRFs Build Scenarios (3-Examples)



**Concomitant medication** [OID=F.CM\_2011-10-24]

---

**General information**  
[OID=IG.CMYN\_2011-10-24]

Any meds?  NO [N]  YES [Y]  
[OID=CM\_1\_2011-10-24|CDASH=CMYN] [OID=CL.NY.SUB.Y.N\_2011-10-24]

---

**1st. Details**  
[OID=IG.CM\_2011-10-24|Repeating]

Medication or Therapy  
[OID=CM\_3\_2011-10-24|CDASH=CMTRT|CDASH/SDTM=CMTRT]

---

Taken Prior to Study?  NO [N]  YES [Y]  
[OID=CM\_19\_2011-10-24|CDASH=CMPRIOR] [OID=CL.NY.SUB.Y.N\_2011-10-24]

Start Date \_\_\_\_\_ dd-mmm-yyyy  
[OID=CM\_17\_2011-10-24|CDASH=CMSTDAT]

Ongoing  NO [N]  YES [Y]  
[OID=CM\_23\_2011-10-24|CDASH=CMONGO] [OID=CL.NY.SUB.Y.N\_2011-10-24]

End Date \_\_\_\_\_ dd-mmm-yyyy  
[OID=CM\_21\_2011-10-24|CDASH=CMENDAT]

**Exposure Form**

**EXSTDAT** Start Date (dd- MMM- yyyy) \_\_\_\_\_

**EXSTTIM** Actual Start Time \_\_\_\_\_

**EXENTIM** Actual End Time \_\_\_\_\_

**EXIVINTR** Was the infusion temporarily interrupted for more than 10 minutes at a time? Yes  No

**EXINTTIM** Actual Time of Interruption \_\_\_\_\_

Was the planned dose administered? Yes  No

**EXPOCCUR** \_\_\_\_\_

**EXVAMT** If 'No,' specify the total amount administered (mL) \_\_\_\_\_

**AEDSL** If 'No' due to AE, select corresponding AE log line number, start date, and term \_\_\_\_\_

**AESPID** AE log line number \_\_\_\_\_



# LPO Impact Analysis: Beta Release GLIB (1)

#	Document	LPO Findings/ Recommendations/ Questions	Decision
1	GLIB ALS	<p>04/18/2019: I'm assuming a new release of the Controlled Terminology (CT) will be released prior to July. I wanted to confirm the final ALS release will contain the most up-to-date information. KL</p> <p>With the final release in July, will the GLIB and other ALS files be updated using the newest CDASH and SDTM controlled terminology packages?</p>	<p>CTSU will do an impact analysis (for CT Packages released by CDISC before July 2019) to understand the potential impact to our timeline.</p> <p>The intent is to provide documents as current as possible to CDISC releases/ updates; this must be done in consideration of the implementation timelines.</p>
2	GLIB Release Notes: Section 3.2 Standard Conventions – Table 6	<p>This table states that we cannot modify the Field OID. However, on the Variable Naming NVS webinar (3/28), Shannon presented several instances where it is expected and best practice to rename field OIDs in Rave for data collection purposes. In addition, the guide provides examples in 6.3 where it is OK/expected to change the field OIDs thus conflicting with the table. Please confirm Table 6 will be updated to reflect this.</p>	<p>05/02/2019 CDISC Integration FG:</p> <ul style="list-style-type: none"> <li>LPOs can not change the field OIDs on Standard Forms</li> <li>LPOs can change the field OIDs on Non-Standard forms if they have a strong reason to do so.</li> </ul> <p>“Standard Forms” applies to the CTSU Standard Forms ALS, “Non-Standard Forms applies to variables not specified in the CTSU Standard Forms ALS.</p>
3	GLIB Release Notes: Section 3.2 Standard Conventions – Table 7	<p>Given the needed updates to the Field OID to be specific (see situations/comment from 2), the SAS label should be modified for Rave data collection to ensure our programmers using CDASH Rave outputs can correctly identify the fields using the OIDs and Labels. Therefore, the SAS Label should be allowed to be modified when the Form OID is changed. (When data is transformed into SDTM format, the SAS Label can also be updated)</p>	<p>Maintain the same SAS label as in the CDISC GLIB for consistency across LPOs.</p>
4	GLIB ALS	<p>In the ALS, the Field name is the Variable Label + PID. Why the Variable Label? At the Alliance, we find having the Field Name match the Field OID + PID is much easier for specification writing, debugging and general viewing. (Medidata help guides state that in most cases, the Field name is the same as the Field OID.) As far as we understand, the Field Name isn't used for anything site facing or outputs. If the global ALS will not be changed, can the Alliance modify this?</p>	<p>No changes to the Rave Field Names in the CDISC GLIB ALS and CDISC CTSU Standard Forms ALS; the default naming convention will remain as-is, “the caDSR Long Name of the CDE + PID details”.</p> <p>LPOs can use “the caDSR Long Name of the CDE + PID details” or choose to use “the caDSR Short Name of the CDE + PID details” as the Rave field name as needed. If the LPO chooses to use “the caDSR Short Name of the CDE + PID details” for the Rave field name, they are responsible for this update in Rave.</p>

# LPO Impact Analysis: Beta Release GLIB (2)

#	Document	LPO Findings/ Recommendations/ Questions	Decision
5	GLIB Release Notes: Table 6	For the User Data String, Table 6 states we must use the NCI Preferred term. However, CDISC training has stated we can use the NCI Preferred Term or CDISC Synonym. Please clarify which is correct.	<p>LPOs can decide to use the NCI Preferred Term or the CDISC Synonym for the User Data String in Rave.</p> <p>If LPOs decide to use the CDISC Synonym instead of the NCI Preferred Term, they will be responsible for related study build activities and mapping activities for SDTM submission.</p> <p>The 'CDISC GLIB Release Notes' document will be updated to provide details for use of the CDISC Synonym versus the NCI Preferred Term.</p> <p>The CDISC GLIB ALS will remain as is, no changes will be made to the User Data String and NCI Preferred Terms.</p>
6	GLIB ALS	<p>Why is the Data Dictionary Name not modifiable? Some dictionaries will be used across several fields; however, different sub-sets of responses will be needed for the questions.</p> <p>i. Rave does not allow us to subset the dictionary choices at the field level – a separate dictionary must be created</p> <p>ii. Example: NY. Sometimes Unknown or Not Applicable are not valid responses for a question</p> <p>iii. The Alliance would be open to a standard naming convention in this situation.</p>	<p>If authoring a form directly in Rave: LPOs should use the vetted CSC Data Elements Work Group (DEWG) naming convention (caDSR Value Domain Long Name + PID + MajorV + MinorV + _OF) for dictionary names and append an integer when subsetting a dictionary.</p> <p>If building a form in the caDSR/ using the OCI to import the form into Rave: the OCI will append an integer to the dictionary name when a dictionary is reused/ subsetted.</p> <p>Dictionary Names have been reverted to No changes will be made to the CDISC GLIB ALS. The CDISC GLIB Release Notes will be updated to include this naming convention for subsetted dictionary names.</p>
7	GLIB ALS	When the GLIB is updated/versioned, can we get a detailed change log with the future releases?	A change log will be provided in the release notes for each updated GLIB release.

# LPO Impact Analysis: Beta Release GLIB (3)

#	Document	LPO Findings/ Recommendations/ Questions	Decision
8	NCI/CDISC Best Practices Document	<p>04/18/2019: In this section, it talked about all of these documents needed to be provided. I'm curious if there is any guidance to expected/required format and/or the level that we have to have prepared for CTEP-IND trials. We do not submit data directly to the FDA; I'm curious if we have to have annotated CRFs, and all these other documents that are listed for all trials. And if the trial has intent to submit to FDA, can we negotiate with our pharma partner on these. KL</p> <p>Section 4.3: What does this mean for us as LPO's? We are not translating all of these statements into what actions need to be done on Alliance trials. (Maybe the training is still coming?)</p>	<p>All CTEP IND studies activated on/after 1/1/2020 must be CDISC compliant.</p> <p>CDISC Compliance is highly recommended for studies that activate prior to the 2020 date.</p> <p>The CDISC SME to provide additional feedback at the "Overview of FDA Submission Process" Webinar on May 22nd, 2019.</p>
9	NCI/CDISC Best Practices Document	Could a real life example/demo of the described best practices for the Eligibility Checklist Forms be provided? We're not following the workflows, when to curate/not curate, etc.	The CBIIT caDSR team presented the curation support/process for eligibility criteria at the December Committee Meeting and an overview of this process at the April Committee Meeting.
10	NCI/CDISC Best Practices Document	Does NCI/CTEP submit data to FDA on NCTN trials? If so, study by study or aggregated across studies?	No decision required, NCI does not submit to the FDA.
11	NCI/CDISC Best Practices Document	<p>Throughout the entire document, please be specific what CDISC compliant means. CDASH, SDTM, ADaM, etc.</p> <p>a. Additionally, our understanding from previous meetings is that the requirement is to be CDASH compliant only. We understood that it is up to the LPOs discretion and negotiations with the Pharma partner on SDTM programming. Please be specific in the document about whether we are referring to CDISC-CDASH or CDISC-SDTM.</p>	<p>The FDA requirement is SDTM. the NCI requirement is CDASH.</p> <p>CDASH compliance makes SDTM compliance easier to achieve.</p> <p>CDISC PM to review and update the NCI CDISC Best Practices document as needed to ensure clear communication of the NCI requirement for CDASH compliance.</p>



**NATIONAL  
CANCER  
INSTITUTE**

[www.cancer.gov](http://www.cancer.gov)

[www.cancer.gov/espanol](http://www.cancer.gov/espanol)